Predictors and prognostic relevance of tricuspid alterations in patients undergoing transcatheter edge-to-edge mitral valve repair.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
19 Nov 2021
Historique:
pubmed: 2 3 2021
medline: 23 11 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

Mitral valve repair may lead to alterations of tricuspid regurgitation (TR). We aimed to investigate alterations, predictors and prognostic relevance of TR evolution in a large-scale multicentre population of patients undergoing transcatheter mitral valve repair (TMVR) via the MitraClip. In total, we included 531 TMVR patients with at least one available follow-up echocardiography. TR improvement was defined as a TR ≥II at baseline, which showed a decline of at least one TR categorisation. Distribution of preprocedural TR severity was TR 0/I 41% (220/531), TR II 39% (209/531) and TR ≥III 19% (102/531), respectively. Follow-up echocardiography was at 308±187 days. TR severity improved to TR 0/I 49% (259/531), TR II 35% (183/531) and TR III 17% (89/531), p=0.003. Out of 311 patients with TR ≥II at baseline, 41% (127/311) showed TR improvement. Atrial fibrillation (AF), residual mitral regurgitation ≥II (rMR) and tricuspid annular diameter (TAD) remained variables which prevented TR improvement (odds ratio 0.49 [0.29-0.84], 0.47 [0.27-0.81] and 0.97 [0.93-0.997], respectively). TR improvement was associated with better event-free survival regarding post-procedural heart failure hospitalisation (HHF) (hazard ratio 0.6 [0.38-0.94]). The main changes of TR severity occurred within 3 months post TMVR (p=0.006), while there were only minor TR changes between 3 and 12 months of follow-up (p=0.813). TR improvement was frequent after TMVR. Predictors preventing TR improvement were AF, post-procedural rMR, and TAD. Furthermore, TR improvement was an early phenomenon occurring primarily within the first three months post TMVR and served as a suitable marker of reduced HHF.

Sections du résumé

BACKGROUND BACKGROUND
Mitral valve repair may lead to alterations of tricuspid regurgitation (TR).
AIMS OBJECTIVE
We aimed to investigate alterations, predictors and prognostic relevance of TR evolution in a large-scale multicentre population of patients undergoing transcatheter mitral valve repair (TMVR) via the MitraClip.
METHODS METHODS
In total, we included 531 TMVR patients with at least one available follow-up echocardiography. TR improvement was defined as a TR ≥II at baseline, which showed a decline of at least one TR categorisation.
RESULTS RESULTS
Distribution of preprocedural TR severity was TR 0/I 41% (220/531), TR II 39% (209/531) and TR ≥III 19% (102/531), respectively. Follow-up echocardiography was at 308±187 days. TR severity improved to TR 0/I 49% (259/531), TR II 35% (183/531) and TR III 17% (89/531), p=0.003. Out of 311 patients with TR ≥II at baseline, 41% (127/311) showed TR improvement. Atrial fibrillation (AF), residual mitral regurgitation ≥II (rMR) and tricuspid annular diameter (TAD) remained variables which prevented TR improvement (odds ratio 0.49 [0.29-0.84], 0.47 [0.27-0.81] and 0.97 [0.93-0.997], respectively). TR improvement was associated with better event-free survival regarding post-procedural heart failure hospitalisation (HHF) (hazard ratio 0.6 [0.38-0.94]). The main changes of TR severity occurred within 3 months post TMVR (p=0.006), while there were only minor TR changes between 3 and 12 months of follow-up (p=0.813).
CONCLUSIONS CONCLUSIONS
TR improvement was frequent after TMVR. Predictors preventing TR improvement were AF, post-procedural rMR, and TAD. Furthermore, TR improvement was an early phenomenon occurring primarily within the first three months post TMVR and served as a suitable marker of reduced HHF.

Identifiants

pubmed: 33646125
pii: EIJ-D-20-01094
doi: 10.4244/EIJ-D-20-01094
pmc: PMC9724950
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

827-834

Références

J Am Coll Cardiol. 2015 Jun 2;65(21):2331-6
pubmed: 26022823
Eur Heart J Cardiovasc Imaging. 2014 Nov;15(11):1246-55
pubmed: 24939944
EuroIntervention. 2016 Apr 08;11(14):e1680-6
pubmed: 27056128
Clin Res Cardiol. 2017 May;106(5):350-358
pubmed: 27999930
EuroIntervention. 2017 Feb 3;12(15):e1817-e1824
pubmed: 28117278
EuroIntervention. 2017 Feb 3;12(15):e1809-e1816
pubmed: 28089952
Lancet. 2019 Nov 30;394(10213):2002-2011
pubmed: 31708188
J Am Coll Cardiol. 2005 Dec 6;46(11):2134-40
pubmed: 16325053
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
JACC Cardiovasc Interv. 2020 Mar 9;13(5):543-550
pubmed: 31954679
Lancet. 2016 Nov 12;388(10058):2431-2442
pubmed: 27048553
Am J Cardiol. 2018 Jun 1;121(11):1343-1350
pubmed: 29580628
J Am Coll Cardiol. 2009 Feb 3;53(5):401-8
pubmed: 19179197
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Eur Heart J. 2012 Oct;33(19):2451-96
pubmed: 22922415
Circulation. 2014 Jun 10;129(23):2440-92
pubmed: 24589852
Am J Cardiol. 2017 Sep 1;120(5):857-861
pubmed: 28689751
Circulation. 2017 Jun 20;135(25):e1159-e1195
pubmed: 28298458
J Am Coll Cardiol. 2019 Apr 23;73(15):1905-1915
pubmed: 30999993
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH